Clinical trials: Elevated Cholesterol
Overweight, Hypercholesterolemia
Supplementation of Alpha-linolenic Acid (ALA)-Rich Oil in Humans
The objective of this study is to investigate the accumulation of n-3 LC-PUFA (EPA, DPA and DHA) in human lipids by oral supplementation of ALA-rich linseed oil.
- Trial name
- ALA_KK (NCT01317290)
- Testing
- n-3 PUFA free olive oil, linseed oil
- Where
- Germany
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of Jena
Hypercholesterolemia
A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)
The purpose of this study is to investigate the effect of an investigational cholesterol-lowering drug in patients who are currently taking an approved medication for hypercholesterolemia (high cholesterol levels) and have been…
- Trial name
- NCT00132717
- Testing
- MK0653A (ezetimibe [+] simvastatin), Comparator: atorvastatin, Comparator: fluvastatin
- Volunteers
- 450 people
- Sponsor
- Organon and Co
HIV-Associated Lipodystrophy Syndrome
Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients
Highly active antiretroviral therapy (HAART) has improved the long time survival of HIV infected individuals. However an increasing number of HIV-patients have developed metabolic and morphological alterations including…
- Trial name
- NCT00135460
- Testing
- nucleoside analogue sparing HAART regimen
- Where
- 5 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Danish HIV Research Group
Chronic Hepatitis C Viral Infection
Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?
The working hypothesis is that the low HDL serum level predict favorable response to anti viral treatment in chronic HCV (genotype 1) viral infection. This might be used to improve the rate of sustained virologic response.
- Trial name
- NCT01159613
- Testing
- Responders, Non Responders
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Ziv Hospital
Hypercholesterolemia, Hypertension
Evaluating "Health at Every Size"(HAES) as an Alternative Obesity Treatment Model
Increasingly more individuals are trying to lose weight. Indeed, many women, regardless of their size, experience a life-long battle and preoccupation with their weight.
- Conditions
- Hypercholesterolemia, Hypertension, Depression, Diabetes Mellitus, Type 2
- Trial name
- NCT00074633
- Testing
- Health at Every Size (HAES), Diet (Traditional, moderate energy restriction)
- Where
- 2 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Mixed Dyslipidemia, Hypercholesterolaemia
Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
This Phase 3, randomized, double-blind, active-controlled study evaluates the efficacy and safety of obicetrapib (OBI) compared to bempedoic acid (BPA) in participants with dyslipidemia at high or very high cardiovascular risk.
- Trial name
- MEDICI (NCT07614958)
- Where
- United Kingdom
- Volunteers
- 426 people
- Sponsor
- A. Menarini International Licensing S.A.
HIV Infections
Impact of HIV and Its Treatment on Reverse Cholesterol Transport
To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on individual steps of reverse cholesterol transport, endothelial function and intima-media thickness in HIV patients.
- Trial name
- NCT00168233
- Where
- Australia
- Volunteers
- 44 people
- Sponsor
- The Alfred
Homozygous Familial Hypercholesterolemia HoFH
Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia
To describe the safety and tolerability of evolocumab in participants with homozygous familial hypercholesterolemia (HoFH) in India. All participants will receive evolocumab over an 8-week period.
- Trial name
- RAMAN (NCT03403374)
- Testing
- evolocumab
- Where
- 12 sites in India
- Volunteers
- 30 people
- Sponsor
- Amgen
Cardiovascular Diseases
Impact of Statin Therapy on Adaptations to Aerobic Exercise
The purpose of this study is to determine how different doses of a statin affect muscle health and exercise.
- Trial name
- NCT03360916
- Testing
- Lipitor 20Mg Tablet, Lipitor 80Mg Tablet, Exercise Program
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Cardiovascular Diseases, Hypercholesterolemia
Plant Sterols on Cardiovascular Markers, Microbiota and Sterol Metabolism (Cardiofoodsterol)
Potential cholesterol-lowering effect of a regular intake of a plant sterol (PS)-containing food supplement, in overweight/obese type 1 or 2, normoglycemic/pre-diabetic, with LDL-cholesterol values > 115 mg/dl and not…
- Conditions
- Cardiovascular Diseases, Hypercholesterolemia, Prediabetic State, Overweight and Obesity
- Trial name
- NCT06481020
- Testing
- Plant sterols 2g/day
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- University of Valencia
Heterozygous Familial Hypercholesterolemia
Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in participants with Heterozygous Familial…
- Trial name
- NCT03038022
- Testing
- MGL-3196 (resmetirom)
- Where
- 13 sites in Denmark, Netherlands and 1 more
- Volunteers
- 116 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Metabolic Syndrome X
A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism
Agents that increase HDL-C via reverse cholesterol transport could provide a new therapeutic option for the prevention of atherosclerotic cardiovascular disease.
- Trial name
- NCT00327002
- Testing
- LY518674
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
Elevated LDL-C and High Cholesterol
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. STX-1150 does not edit or permanently change the gene.
- Trial name
- STX-1150-01 (NCT07428473)
- Testing
- STX-1150
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 64 people
- Sponsor
- Monash University
Hypercholesterolemia, Hyperlipoproteinemia
A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin
Lifibrol is a new lipid-lowering drug which lowers cholesterol to an extent in the order of magnitude of the statins. The mechanism of action of this compound is different from the one of statins but remains unknown.
- Trial name
- NCT01057654
- Testing
- Pravastatin, Lifibrol
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Lipoprotein Disorder
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
The main purpose of this study is to evaluate the efficacy and safety of LY3473329 in adult participants with elevated Lp(a) at high risk for cardiovascular events.
- Trial name
- KRAKEN (NCT05563246)
- Testing
- LY3473329
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 233 people
- Sponsor
- Eli Lilly and Company
Dyslipidemia, Diabetes
Meta-analyses of the Effect of Important Food Sources of Sugars on Cardiometabolic Risk Factors
Fructose-containing sugars have been implicated in the epidemics of obesity, diabetes and related cardiometabolic disorders. This view is supported by lower quality evidence from ecological observations, animal models, and select…
- Conditions
- Dyslipidemia, Diabetes, Prediabetes, Dysglycemia
- Trial name
- NCT02716870
- Testing
- Fructose-containing Sugars
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Obesity, Overweight
Pediatric Preventative Health Screenings - Obesity and Family-Centered Outcomes
In 2012, an Expert Panel of the National Heart Lung and Blood Institute published guidelines on cardiovascular health and risk reduction in children; among these guidelines were screening recommendations for obesity and…
- Conditions
- Obesity, Overweight, Blood Pressure, Hypercholesteremia
- Trial name
- NCT02850224
- Testing
- Motivational interviewing to elicit PCO in pediatrics
- Where
- United States
- Volunteers
- 703 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Primary Hypercholesterolemia
A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)
This is a study to evaluate the lipid-altering efficacy, safety, and tolerability of ezetimibe when added to ongoing therapy with an 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) in participants…
- Trial name
- NCT03882905
- Testing
- Ezetimibe, Simivastatin, Statin
- Volunteers
- 769 people
- Sponsor
- Organon and Co
Cardiac Disease, Cancer
Electronic Medical Records and Genomics (eMERGE) Phase III
The Electronic Medical Records and Genomics (eMERGE) Network is in its third phase and during this time is enrolling and sequencing 25,000 individuals on a custom sequencing panel of clinically relevant, actionable genes.
- Conditions
- Cardiac Disease, Cancer, Hypercholesterolemia, Diabetes
- Trial name
- eMERGE (NCT03394859)
- Volunteers
- 25,380 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Hypercholesterolemia
Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia
The present study is assessing the efficacy and safety of AVE5530 (25 mg and 50 mg) in add-on to ongoing treatment with high doses of statin in a double-blind manner in comparison with placebo, in the management of patients with…
- Trial name
- NCT00766688
- Testing
- AVE5530
- Where
- 13 sites in United States, Australia and 11 more
- Volunteers
- 643 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.